Novavax COVID-19 vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Novavax COVID-19 vaccine" in English language version.

refsWebsite

Global rank English rank

84web.archive.org

1^st place

27nih.gov

4^th place

15doi.org

2^nd place

12tga.gov.au

3,984^th place

2,622^nd place

10europa.eu

68^th place

117^th place

7reuters.com

49^th place

47^th place

7fda.gov

447^th place

338^th place

6semanticscholar.org

11^th place

8^th place

5novavax.com

low place

4worldcat.org

5^th place

4nytimes.com

7^th place

3cnbc.com

220^th place

155^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

3canada.ca

1,712^th place

1,063^rd place

2bbc.com

20^th place

30^th place

2harvard.edu

18^th place

17^th place

2bizjournals.com

407^th place

241^st place

2washingtonpost.com

34^th place

27^th place

2fiercepharma.com

low place

8,921^st place

2statnews.com

8,771^st place

5,253^rd place

2cdc.gov

218^th place

212^th place

2hres.ca

low place

2thackraymuseum.co.uk

low place

2cnn.com

28^th place

26^th place

1gov.uk

432^nd place

278^th place

1globenewswire.com

2,614^th place

1,549^th place

1nps.org.au

low place

1hpfb-dgpsa.ca

low place

1livemint.com

390^th place

227^th place

1medpagetoday.com

9,274^th place

5,856^th place

1handle.net

102^nd place

76^th place

1oclc.org

1,391^st place

1,017^th place

1rxfiles.ca

low place

1takeda.com

low place

1thisistherealspain.com

low place

1bloomberg.com

99^th place

77^th place

1aljazeera.com

268^th place

215^th place

1theprint.in

987^th place

560^th place

1docs.google.com

1,047^th place

1,015^th place

1theguardian.com

12^th place

11^th place

1gazettelive.co.uk

5,758^th place

3,245^th place

1abc.net.au

139^th place

108^th place

1latimes.com

22^nd place

19^th place

1ndtv.com

138^th place

95^th place

1straitstimes.com

543^rd place

346^th place

1channelnewsasia.com

1,127^th place

691^st place

1who.int

195^th place

302^nd place

1yahoo.com

38^th place

40^th place

1apnews.com

129^th place

89^th place

1globo.com

62^nd place

304^th place

1ebc.com.br

2,752^nd place

6,664^th place

abc.net.au (Global: 139^th place; English: 108^th place)

"Human trials of potential coronavirus vaccine begin in Melbourne". Australian Broadcasting Corporation. 25 May 2020. Archived from the original on 2 June 2021. Retrieved 27 July 2021.

aljazeera.com (Global: 268^th place; English: 215^th place)

"EU approves Novavax shot as fifth COVID vaccine". Al Jazeera English. Archived from the original on 21 December 2021. Retrieved 21 December 2021.

apnews.com (Global: 129^th place; English: 89^th place)

Neergaard L (19 July 2022). "CDC endorses more traditional Novavax COVID shot for adults". Associated Press. Archived from the original on 22 July 2022. Retrieved 21 July 2022.

bbc.com (Global: 20^th place; English: 30^th place)

"New Covid vaccine shows 89% efficacy in UK trials". BBC News. 28 January 2021. Archived from the original on 30 January 2021. Retrieved 28 January 2021.
Reed J (3 February 2022). "Novavax Covid jab approved by UK drugs regulator". BBC News. Archived from the original on 3 February 2022. Retrieved 3 February 2022.

bizjournals.com (Global: 407^th place; English: 241^st place)

Gilgore S (26 February 2020). "Novavax is working to advance a potential coronavirus vaccine. So are competitors". Washington Business Journal. Archived from the original on 16 March 2020. Retrieved 6 March 2020.
Gilgore S (10 March 2020). "Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions". Washington Business Journal. Archived from the original on 9 April 2020. Retrieved 10 March 2020.

bloomberg.com (Global: 99^th place; English: 77^th place)

Bujnicki P, Krasuski K (25 March 2021). "Novavax Deal With Mabion Boosts Poland's Nascent Biotech Scene". Bloomberg. Archived from the original on 9 March 2021. Retrieved 24 March 2021.

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

canada.ca

"Novavax Nuvaxovid COVID-19 vaccine". Health Canada. 17 February 2022. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
"Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine" (Press release). Ottawa: Health Canada. 17 February 2022. Archived from the original on 17 February 2022. Retrieved 17 February 2022.

covid-vaccine.canada.ca

"Nuvaxovid". Health Canada. 17 February 2022. Archived from the original on 1 June 2022. Retrieved 31 May 2022.

cdc.gov (Global: 218^th place; English: 212^th place)

"CDC Recommends Novavax's COVID-19 Vaccine for Adults" (Press release). Centers for Disease Control and Prevention. 19 July 2022. Archived from the original on 20 July 2022. Retrieved 21 July 2022.
"CDC Recommends Novavax COVID-19 Vaccine for Adolescents" (Press release). US Centers for Disease Control and Prevention. 22 August 2022. Archived from the original on 3 September 2022. Retrieved 3 September 2022.

channelnewsasia.com (Global: 1,127^th place; English: 691^st place)

Andres G (14 February 2022). "Novavax's Nuvaxovid COVID-19 vaccine granted interim authorisation in Singapore". CNA. Archived from the original on 11 March 2022. Retrieved 6 March 2022.

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom". United States National Library of Medicine. 12 October 2021. Archived from the original on 25 May 2021. Retrieved 13 August 2020.
Clinical trial number NCT04611802 for "A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2" at ClinicalTrials.gov
Clinical trial number NCT04533399 for "A Phase 2A/B, Randomized,Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV" at ClinicalTrials.gov

cnbc.com (Global: 220^th place; English: 155^th place)

"Novavax starts clinical trial of its coronavirus vaccine candidate". CNBC. 25 May 2020. Archived from the original on 26 May 2020. Retrieved 26 May 2020.
Lovelace B (28 January 2020). "Novavax says Covid vaccine is more than 89% effective". CNBC. Archived from the original on 30 January 2021. Retrieved 28 January 2021.
Kimball S (9 June 2022). "FDA decision on Novavax's Covid shots could be delayed to review changes in manufacturing". CNBC. Archived from the original on 9 June 2022. Retrieved 9 June 2022.

cnn.com (Global: 28^th place; English: 26^th place)

edition.cnn.com

Howard J (14 June 2021). "Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial". CNN. Archived from the original on 14 June 2021. Retrieved 14 June 2021.

cnn.com

Christensen J, Goodman B (13 July 2022). "FDA gives emergency use authorization to Novavax's Covid-19 vaccine". CNN. Archived from the original on 14 July 2022. Retrieved 14 July 2022.

docs.google.com (Global: 1,047^th place; English: 1,015^th place)

"COVID-19 vaccine tracker (click on 'Vaccines' tab)". Milken Institute. 11 May 2020. Archived from the original on 6 June 2020. Retrieved 12 May 2020.

doi.org (Global: 2^nd place; English: 2^nd place)

"SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. (December 2021). "Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico". primary. New England Journal of Medicine. 386 (6): 531–543. doi:10.1056/NEJMoa2116185. PMC 8693692. PMID 34910859.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". secondary. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". primary. Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. hdl:1959.4/105023. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. (June 2021). "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine". primary. The New England Journal of Medicine. 385 (13): 1172–1183. doi:10.1056/NEJMoa2107659. PMC 8262625. PMID 34192426. S2CID 235697707.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. (May 2021). "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant". primary. The New England Journal of Medicine. 384 (20): 1899–1909. doi:10.1056/NEJMoa2103055. PMC 8091623. PMID 33951374.
Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, et al. (December 2023). "The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century". primary. Human Vaccines & Immunotherapeutics. 19 (1) 2189885. doi:10.1080/21645515.2023.2189885. PMC 10158541. PMID 37113023.
Wadman M, Jon C (28 January 2021). "Novavax vaccine delivers 89% efficacy against COVID-19 in UK – but is less potent in South Africa". Science. doi:10.1126/science.abg8101. S2CID 234058820.
Wadman M (November 2020). "The long shot". comment. Science. 370 (6517): 649–653. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120. S2CID 226270339.
Wadman M (28 December 2020). "Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays". Science. doi:10.1126/science.abg3441. S2CID 234411557.
Chung YH, Beiss V, Fiering SN, Steinmetz NF (October 2020). "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design". secondary. ACS Nano. 14 (10): 12522–12537. Bibcode:2020ACSNa..1412522C. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D (June 2020). "Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles". primary. ACS Nano. 14 (6): 7617–7627. doi:10.1021/acsanm.0c01978. PMC 7482545. PMID 32437124.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". secondary. Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Majumder J, Minko T (January 2021). "Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19". secondary. The AAPS Journal. 23 (1) 14. doi:10.1208/s12248-020-00532-2. PMC 7784226. PMID 33400058.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. (May 2021). "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant". primary. The New England Journal of Medicine. 384 (20): 1899–1909. doi:10.1056/NEJMoa2103055. PMC 8091623. PMID 33951374.

ebc.com.br (Global: 2,752^nd place; English: 6,664^th place)

agenciabrasil.ebc.com.br

"COVID-19 vaccine Zalika is registered in Brazil". Agência Brasil. 9 January 2024. Retrieved 13 December 2024.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Nuvaxovid EPAR". European Medicines Agency (EMA). 17 December 2021. Archived from the original on 23 December 2021. Retrieved 23 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)" (Press release). European Medicines Agency (EMA). 3 February 2021. Archived from the original on 2 July 2021. Retrieved 30 June 2021.
"EMEA-002941-PIP01-20". European Medicines Agency (EMA). 16 March 2021. Archived from the original on 21 June 2021. Retrieved 29 June 2021.
"COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.
"COVID-19 vaccines safety update" (PDF). European Medicines Agency. 3 August 2022. Archived (PDF) from the original on 3 August 2022. Retrieved 3 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024". European Medicines Agency (EMA). 18 October 2024. Retrieved 21 October 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA receives application for conditional marketing authorisation of Novavax's COVID-19 vaccine, Nuvaxovid". European Medicines Agency (EMA). 17 November 2021. Archived from the original on 1 December 2021. Retrieved 5 December 2021.
"EMA recommends Nuvaxovid for authorisation in the EU" (Press release). European Medicines Agency (EMA). 20 December 2021. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
"Nuvaxovid : EPAR - Product information" (PDF). European Medicines Agency. 5 July 2022. Archived (PDF) from the original on 17 August 2022. Retrieved 11 August 2022.

ec.europa.eu

"Nuvaxovid". Union Register of medicinal products. European Commission. 6 July 2022. Archived from the original on 20 December 2021. Retrieved 23 December 2021.

fda.gov (Global: 447^th place; English: 338^th place)

"Nuvaxovid". U.S. Food and Drug Administration. 16 May 2025. Archived from the original on 19 May 2025. Retrieved 19 May 2025. This article incorporates text from this source, which is in the public domain.
https://www.fda.gov/media/188446/download
"FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA) (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted | FDA". U.S. Food and Drug Administration. 13 July 2022. Archived from the original on 15 July 2022. Retrieved 15 July 2022.
"FDA Roundup: August 19, 2022". U.S. Food and Drug Administration (Press release). 19 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022.
"Novavax COVID-19 Vaccine, Adjuvanted". U.S. Food and Drug Administration (FDA). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
"FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA) (Press release). 30 August 2024. Archived from the original on 4 September 2024. Retrieved 31 August 2024.

fiercepharma.com (Global: low place; English: 8,921^st place)

Sagonowsky E (11 May 2020). "Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work". FiercePharma. Archived from the original on 16 May 2020. Retrieved 12 May 2020.
Dunleavy K (10 May 2024). "Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform". Fierce Pharma. Retrieved 6 August 2024.

gazettelive.co.uk (Global: 5,758^th place; English: 3,245^th place)

Brown M (14 August 2020). "60m doses of new covid-19 vaccine could be made in Billingham – and be ready for mid-2021". Teesside News. Archived from the original on 7 February 2021. Retrieved 29 January 2021.

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

"Novavax and Takeda Finalize License Agreement for Novavax' COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan" (Press release). GlobeNewswire. 26 February 2021. Archived from the original on 2 June 2021. Retrieved 29 May 2021.

globo.com (Global: 62^nd place; English: 304^th place)

g1.globo.com

"Ministério da Saúde anuncia como será a vacinação contra Covid em 2025" [Ministry of Health announces how Covid vaccination will be carried out in 2025]. G1 (in Portuguese). 12 December 2024. Retrieved 13 December 2024.

gov.uk (Global: 432^nd place; English: 278^th place)

"Regulatory approval of COVID-19 vaccine Nuvaxovid". Medicines and Healthcare products Regulatory Agency (MHRA). 3 February 2022. Archived from the original on 3 February 2022. Retrieved 3 February 2022.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". primary. Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. hdl:1959.4/105023. ISSN 1546-170X. PMID 34002089. S2CID 234769053.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Wadman M (November 2020). "The long shot". comment. Science. 370 (6517): 649–653. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120. S2CID 226270339.
Chung YH, Beiss V, Fiering SN, Steinmetz NF (October 2020). "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design". secondary. ACS Nano. 14 (10): 12522–12537. Bibcode:2020ACSNa..1412522C. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

"Summary Basis of Decision (SBD) for Nuvaxovid XBB.1.5". Health Canada. 9 February 2024. Retrieved 24 February 2024.

hres.ca (Global: low place; English: low place)

pdf.hres.ca

Novavax, Inc. (24 March 2022). "Product Monograph, NUVAXOVID ™, COVID-19 Vaccine (Recombinant protein, Adjuvanted)" (PDF). Archived (PDF) from the original on 29 May 2022. Retrieved 14 July 2022.

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Nuvaxovid". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

latimes.com (Global: 22^nd place; English: 19^th place)

Johnson L (14 June 2021). "Large study finds that vaccine maker Novavax's shot is about 90% effective". Los Angeles Times. Archived from the original on 18 June 2021. Retrieved 15 June 2021.

livemint.com (Global: 390^th place; English: 227^th place)

Leo L (27 March 2021). "Hope to launch Covovax by September, says Serum Institute CEO". mint. Archived from the original on 13 May 2021. Retrieved 28 March 2021.

medpagetoday.com (Global: 9,274^th place; English: 5,856^th place)

Henderson J (1 January 2022). "What Happened to the Novavax Vaccine?". MedPage Today. Archived from the original on 7 February 2022. Retrieved 5 February 2022.

ndtv.com (Global: 138^th place; English: 95^th place)

Achom D (28 December 2021). "India Clears 2 New Vaccines And Merck's Covid Pill". NDTV.com. Archived from the original on 28 December 2021. Retrieved 28 December 2021.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

"SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. (December 2021). "Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico". primary. New England Journal of Medicine. 386 (6): 531–543. doi:10.1056/NEJMoa2116185. PMC 8693692. PMID 34910859.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". secondary. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". primary. Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. hdl:1959.4/105023. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. (June 2021). "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine". primary. The New England Journal of Medicine. 385 (13): 1172–1183. doi:10.1056/NEJMoa2107659. PMC 8262625. PMID 34192426. S2CID 235697707.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. (May 2021). "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant". primary. The New England Journal of Medicine. 384 (20): 1899–1909. doi:10.1056/NEJMoa2103055. PMC 8091623. PMID 33951374.
Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, et al. (December 2023). "The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century". primary. Human Vaccines & Immunotherapeutics. 19 (1) 2189885. doi:10.1080/21645515.2023.2189885. PMC 10158541. PMID 37113023.
Wadman M (November 2020). "The long shot". comment. Science. 370 (6517): 649–653. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120. S2CID 226270339.
Chung YH, Beiss V, Fiering SN, Steinmetz NF (October 2020). "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design". secondary. ACS Nano. 14 (10): 12522–12537. Bibcode:2020ACSNa..1412522C. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D (June 2020). "Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles". primary. ACS Nano. 14 (6): 7617–7627. doi:10.1021/acsanm.0c01978. PMC 7482545. PMID 32437124.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". secondary. Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Majumder J, Minko T (January 2021). "Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19". secondary. The AAPS Journal. 23 (1) 14. doi:10.1208/s12248-020-00532-2. PMC 7784226. PMID 33400058.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. (May 2021). "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant". primary. The New England Journal of Medicine. 384 (20): 1899–1909. doi:10.1056/NEJMoa2103055. PMC 8091623. PMID 33951374.

ncbi.nlm.nih.gov

"SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. (December 2021). "Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico". primary. New England Journal of Medicine. 386 (6): 531–543. doi:10.1056/NEJMoa2116185. PMC 8693692. PMID 34910859.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". secondary. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. (June 2021). "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine". primary. The New England Journal of Medicine. 385 (13): 1172–1183. doi:10.1056/NEJMoa2107659. PMC 8262625. PMID 34192426. S2CID 235697707.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. (May 2021). "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant". primary. The New England Journal of Medicine. 384 (20): 1899–1909. doi:10.1056/NEJMoa2103055. PMC 8091623. PMID 33951374.
Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, et al. (December 2023). "The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century". primary. Human Vaccines & Immunotherapeutics. 19 (1) 2189885. doi:10.1080/21645515.2023.2189885. PMC 10158541. PMID 37113023.
"COVID-19 Protein Subunit Vaccine (Novavax)". Mother To Baby Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS). May 2023.
Chung YH, Beiss V, Fiering SN, Steinmetz NF (October 2020). "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design". secondary. ACS Nano. 14 (10): 12522–12537. Bibcode:2020ACSNa..1412522C. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D (June 2020). "Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles". primary. ACS Nano. 14 (6): 7617–7627. doi:10.1021/acsanm.0c01978. PMC 7482545. PMID 32437124.
Majumder J, Minko T (January 2021). "Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19". secondary. The AAPS Journal. 23 (1) 14. doi:10.1208/s12248-020-00532-2. PMC 7784226. PMID 33400058.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. (May 2021). "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant". primary. The New England Journal of Medicine. 384 (20): 1899–1909. doi:10.1056/NEJMoa2103055. PMC 8091623. PMID 33951374.

dailymed.nlm.nih.gov

"Nuvaxovid COVID-19 Vaccine, Adjuvanted- nvx-cov2705 injection, suspension". DailyMed. 5 June 2025. Retrieved 6 July 2025.
"Novavax COVID-19 Vaccine, Adjuvanted- nvx-cov2705 injection, suspension". DailyMed. 3 September 2024. Retrieved 16 September 2024.

nih.gov

"Phase 3 trial of Novavax investigational COVID-19 vaccine opens" (Press release). National Institutes of Health (NIH). 28 December 2020. Archived from the original on 19 January 2021. Retrieved 28 December 2020.

novavax.com (Global: low place; English: low place)

ir.novavax.com

"Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - Oct 3, 2023". Novavax (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
"Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom". Novavax. 24 September 2020. Archived from the original on 14 August 2021. Retrieved 14 August 2021.
"Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine" (Press release). Novavax. 3 May 2021. Archived from the original on 2 June 2021. Retrieved 30 May 2021.
"Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine" (Press release). Novavax. 30 June 2021. Archived from the original on 30 June 2021. Retrieved 30 June 2021.

novavax.com

"Urgent global health needs addressed by Novavax". Novavax. Archived from the original on 12 May 2021. Retrieved 30 January 2021.

nps.org.au (Global: low place; English: low place)

"SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.

nytimes.com (Global: 7^th place; English: 7^th place)

Zimmer C (5 April 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. ISSN 0362-4331. Archived from the original on 28 April 2021. Retrieved 23 April 2021.
Stolberg SG, LaFraniere S, Hamby C (7 April 2021). "Top Official Warned That Covid Vaccine Plant Had to Be 'Monitored Closely'". The New York Times. Archived from the original on 6 May 2021. Retrieved 6 May 2021.
Thomas K (7 July 2020). "U.S. Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine". The New York Times. Archived from the original on 7 July 2020. Retrieved 7 July 2020.
Robbins R, Zimmer C (19 July 2022). "A fourth Covid vaccine is cleared for use in the United States". The New York Times. ISSN 0362-4331. Archived from the original on 21 July 2022. Retrieved 21 July 2022.

oclc.org (Global: 1,391^st place; English: 1,017^th place)

login.uml.idm.oclc.org

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. (30 June 2021). "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine". login.uml.idm.oclc.org. Retrieved 21 April 2024.

reuters.com (Global: 49^th place; English: 47^th place)

"WHO issues emergency use listing to Novavax-Serum Institute's COVID-19 vaccine". Reuters. 17 December 2021. Archived from the original on 17 December 2021. Retrieved 17 December 2021.
"Novavax signs COVID-19 vaccine supply deal with India's Serum Institute". Reuters. 5 August 2020. Archived from the original on 19 March 2021. Retrieved 21 February 2021.
Steenhuysen J (7 July 2020). "U.S. government awards Novavax $1.6 billion for coronavirus vaccine". Reuters. Archived from the original on 14 September 2020. Retrieved 15 September 2020.
O'Donnell C, Nadeem D (1 November 2021). "Novavax COVID-19 vaccine receives first emergency use authorization". Reuters. Archived from the original on 24 December 2021. Retrieved 1 November 2021.
"Philippines approves emergency use of Novavax's COVID-19 vaccine". Reuters. 17 November 2021. Archived from the original on 23 December 2021. Retrieved 17 November 2021.
"S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills". Reuters. 12 January 2022. Archived from the original on 15 January 2022. Retrieved 16 January 2022.
"Novavax's COVID-19 shot authorized in Taiwan for adults". Reuters. 23 June 2022. Archived from the original on 2 July 2022. Retrieved 23 June 2022.

rxfiles.ca (Global: low place; English: low place)

Crawley A, LeBras M, Regier L (February 2024). "COVID-19 PREVENTION" (PDF). Rxfiles. Retrieved 19 April 2024.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". primary. Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. hdl:1959.4/105023. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. (June 2021). "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine". primary. The New England Journal of Medicine. 385 (13): 1172–1183. doi:10.1056/NEJMoa2107659. PMC 8262625. PMID 34192426. S2CID 235697707.
Wadman M, Jon C (28 January 2021). "Novavax vaccine delivers 89% efficacy against COVID-19 in UK – but is less potent in South Africa". Science. doi:10.1126/science.abg8101. S2CID 234058820.
Wadman M (November 2020). "The long shot". comment. Science. 370 (6517): 649–653. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120. S2CID 226270339.
Wadman M (28 December 2020). "Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays". Science. doi:10.1126/science.abg3441. S2CID 234411557.
Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". secondary. Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

Joseph A (10 May 2024). "Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline". STAT. Retrieved 6 August 2024.
Facher L, Joseph A (28 January 2021). "Novavax says its Covid-19 vaccine is 90% effective in late-stage trial". Stat. Archived from the original on 29 January 2021. Retrieved 29 January 2021.

straitstimes.com (Global: 543^rd place; English: 346^th place)

Chong C (14 February 2022). "Novavax Covid-19 vaccine approved for those aged 18 and above in Singapore". The Straits Times. Archived from the original on 9 March 2022. Retrieved 6 March 2022.

takeda.com (Global: low place; English: low place)

"Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan" (Press release). Takeda. 24 February 2021. Archived from the original on 24 February 2021. Retrieved 11 March 2021.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

tga.gov.au

"Nuvaxovid APMDS". Therapeutic Goods Administration (TGA). 20 January 2022. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
"AusPAR: SARS-CoV-2 rS with Matrix-M adjuvant". Therapeutic Goods Administration (TGA). 21 January 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
"AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 27 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
"AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 24 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
"Novavax) (Biocelect Pty Ltd) Labelling Exemption 2022". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 19 March 2023. Retrieved 9 April 2023.
"Nuvaxovid". Australian Public Assessment Report (AusPAR). The Department of Health and Aged Care, Australian Government.
"COVID-19 vaccine safety report - 27-01-2023". Therapeutic Goods Administration (TGA). 27 January 2023. Archived from the original on 31 January 2023. Retrieved 31 January 2023.
"TGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine Nuvaxovid". Therapeutic Goods Administration (TGA) (Press release). 19 January 2022. Archived from the original on 28 January 2022. Retrieved 5 February 2022.
"TGA approves provisional determination for Biocelect Pty Ltd for COVID-19 vaccine, Nuvaxovid". Therapeutic Goods Administration (TGA) (Press release). 10 March 2022. Archived from the original on 8 May 2022. Retrieved 7 May 2022.

ebs.tga.gov.au

"TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 5 February 2022. Retrieved 5 February 2022.

thackraymuseum.co.uk (Global: low place; English: low place)

collections.thackraymuseum.co.uk

"2022.0001 | Collections Online". collections.thackraymuseum.co.uk. Retrieved 21 May 2024.

thackraymuseum.co.uk

"Novavax COVID vaccine has been approved! - Thackray Museum of Medicine". thackraymuseum.co.uk. 4 February 2022. Retrieved 21 May 2024.

theguardian.com (Global: 12^th place; English: 11^th place)

Boseley S, Davis N (28 January 2021). "Novavax Covid vaccine shown to be nearly 90% effective in UK trial". The Guardian. Archived from the original on 12 April 2021. Retrieved 29 January 2021.

theprint.in (Global: 987^th place; English: 560^th place)

Chandna H (26 May 2021). "SII begins manufacturing, stockpiling 2nd Covid vaccine Covovax after Modi govt nod". ThePrint. Archived from the original on 29 May 2021. Retrieved 29 May 2021.

thisistherealspain.com (Global: low place; English: low place)

"Spain, again chosen to produce the vaccine to combat COVID-19". This is the Real Spain. Secretariat of State for Global Spain, Spanish Ministry of Foreign Affairs. 18 September 2020. Archived from the original on 19 March 2021. Retrieved 29 January 2021.

washingtonpost.com (Global: 34^th place; English: 27^th place)

McCartney R (4 May 2020). "Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine". The Washington Post. Archived from the original on 7 May 2020. Retrieved 8 May 2020.
Jeong A (12 January 2022). "South Korea approves Novavax coronavirus vaccine". The Washington Post. Archived from the original on 12 January 2022. Retrieved 15 January 2022.

web.archive.org (Global: 1^st place; English: 1^st place)

"WHO issues emergency use listing to Novavax-Serum Institute's COVID-19 vaccine". Reuters. 17 December 2021. Archived from the original on 17 December 2021. Retrieved 17 December 2021.
"Nuvaxovid APMDS". Therapeutic Goods Administration (TGA). 20 January 2022. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
"Regulatory approval of COVID-19 vaccine Nuvaxovid". Medicines and Healthcare products Regulatory Agency (MHRA). 3 February 2022. Archived from the original on 3 February 2022. Retrieved 3 February 2022.
"Nuvaxovid EPAR". European Medicines Agency (EMA). 17 December 2021. Archived from the original on 23 December 2021. Retrieved 23 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)" (Press release). European Medicines Agency (EMA). 3 February 2021. Archived from the original on 2 July 2021. Retrieved 30 June 2021.
"Novavax and Takeda Finalize License Agreement for Novavax' COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan" (Press release). GlobeNewswire. 26 February 2021. Archived from the original on 2 June 2021. Retrieved 29 May 2021.
"EMEA-002941-PIP01-20". European Medicines Agency (EMA). 16 March 2021. Archived from the original on 21 June 2021. Retrieved 29 June 2021.
"SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
"Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - Oct 3, 2023". Novavax (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
"TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 5 February 2022. Retrieved 5 February 2022.
"AusPAR: SARS-CoV-2 rS with Matrix-M adjuvant". Therapeutic Goods Administration (TGA). 21 January 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
"AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 27 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
"AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 24 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
"Novavax) (Biocelect Pty Ltd) Labelling Exemption 2022". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 19 March 2023. Retrieved 9 April 2023.
Novavax, Inc. (24 March 2022). "Product Monograph, NUVAXOVID ™, COVID-19 Vaccine (Recombinant protein, Adjuvanted)" (PDF). Archived (PDF) from the original on 29 May 2022. Retrieved 14 July 2022.
"Novavax Nuvaxovid COVID-19 vaccine". Health Canada. 17 February 2022. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Nuvaxovid". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
"Nuvaxovid". Health Canada. 17 February 2022. Archived from the original on 1 June 2022. Retrieved 31 May 2022.
"Nuvaxovid". U.S. Food and Drug Administration. 16 May 2025. Archived from the original on 19 May 2025. Retrieved 19 May 2025. This article incorporates text from this source, which is in the public domain.
Leo L (27 March 2021). "Hope to launch Covovax by September, says Serum Institute CEO". mint. Archived from the original on 13 May 2021. Retrieved 28 March 2021.
"FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA) (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023. This article incorporates text from this source, which is in the public domain.
Henderson J (1 January 2022). "What Happened to the Novavax Vaccine?". MedPage Today. Archived from the original on 7 February 2022. Retrieved 5 February 2022.
"COVID-19 vaccines safety update" (PDF). European Medicines Agency. 3 August 2022. Archived (PDF) from the original on 3 August 2022. Retrieved 3 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"COVID-19 vaccine safety report - 27-01-2023". Therapeutic Goods Administration (TGA). 27 January 2023. Archived from the original on 31 January 2023. Retrieved 31 January 2023.
"New Covid vaccine shows 89% efficacy in UK trials". BBC News. 28 January 2021. Archived from the original on 30 January 2021. Retrieved 28 January 2021.
"Urgent global health needs addressed by Novavax". Novavax. Archived from the original on 12 May 2021. Retrieved 30 January 2021.
Zimmer C (5 April 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. ISSN 0362-4331. Archived from the original on 28 April 2021. Retrieved 23 April 2021.
"Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan" (Press release). Takeda. 24 February 2021. Archived from the original on 24 February 2021. Retrieved 11 March 2021.
"Novavax signs COVID-19 vaccine supply deal with India's Serum Institute". Reuters. 5 August 2020. Archived from the original on 19 March 2021. Retrieved 21 February 2021.
"Spain, again chosen to produce the vaccine to combat COVID-19". This is the Real Spain. Secretariat of State for Global Spain, Spanish Ministry of Foreign Affairs. 18 September 2020. Archived from the original on 19 March 2021. Retrieved 29 January 2021.
Bujnicki P, Krasuski K (25 March 2021). "Novavax Deal With Mabion Boosts Poland's Nascent Biotech Scene". Bloomberg. Archived from the original on 9 March 2021. Retrieved 24 March 2021.
"EU approves Novavax shot as fifth COVID vaccine". Al Jazeera English. Archived from the original on 21 December 2021. Retrieved 21 December 2021.
Chandna H (26 May 2021). "SII begins manufacturing, stockpiling 2nd Covid vaccine Covovax after Modi govt nod". ThePrint. Archived from the original on 29 May 2021. Retrieved 29 May 2021.
Gilgore S (26 February 2020). "Novavax is working to advance a potential coronavirus vaccine. So are competitors". Washington Business Journal. Archived from the original on 16 March 2020. Retrieved 6 March 2020.
"COVID-19 vaccine tracker (click on 'Vaccines' tab)". Milken Institute. 11 May 2020. Archived from the original on 6 June 2020. Retrieved 12 May 2020.
Gilgore S (10 March 2020). "Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions". Washington Business Journal. Archived from the original on 9 April 2020. Retrieved 10 March 2020.
McCartney R (4 May 2020). "Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine". The Washington Post. Archived from the original on 7 May 2020. Retrieved 8 May 2020.
Stolberg SG, LaFraniere S, Hamby C (7 April 2021). "Top Official Warned That Covid Vaccine Plant Had to Be 'Monitored Closely'". The New York Times. Archived from the original on 6 May 2021. Retrieved 6 May 2021.
Boseley S, Davis N (28 January 2021). "Novavax Covid vaccine shown to be nearly 90% effective in UK trial". The Guardian. Archived from the original on 12 April 2021. Retrieved 29 January 2021.
Brown M (14 August 2020). "60m doses of new covid-19 vaccine could be made in Billingham – and be ready for mid-2021". Teesside News. Archived from the original on 7 February 2021. Retrieved 29 January 2021.
Sagonowsky E (11 May 2020). "Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work". FiercePharma. Archived from the original on 16 May 2020. Retrieved 12 May 2020.
"Novavax starts clinical trial of its coronavirus vaccine candidate". CNBC. 25 May 2020. Archived from the original on 26 May 2020. Retrieved 26 May 2020.
Thomas K (7 July 2020). "U.S. Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine". The New York Times. Archived from the original on 7 July 2020. Retrieved 7 July 2020.
Steenhuysen J (7 July 2020). "U.S. government awards Novavax $1.6 billion for coronavirus vaccine". Reuters. Archived from the original on 14 September 2020. Retrieved 15 September 2020.
"Human trials of potential coronavirus vaccine begin in Melbourne". Australian Broadcasting Corporation. 25 May 2020. Archived from the original on 2 June 2021. Retrieved 27 July 2021.
"Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom". Novavax. 24 September 2020. Archived from the original on 14 August 2021. Retrieved 14 August 2021.
"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom". United States National Library of Medicine. 12 October 2021. Archived from the original on 25 May 2021. Retrieved 13 August 2020.
"Phase 3 trial of Novavax investigational COVID-19 vaccine opens" (Press release). National Institutes of Health (NIH). 28 December 2020. Archived from the original on 19 January 2021. Retrieved 28 December 2020.
"Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine" (Press release). Novavax. 3 May 2021. Archived from the original on 2 June 2021. Retrieved 30 May 2021.
Lovelace B (28 January 2020). "Novavax says Covid vaccine is more than 89% effective". CNBC. Archived from the original on 30 January 2021. Retrieved 28 January 2021.
"Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine" (Press release). Novavax. 30 June 2021. Archived from the original on 30 June 2021. Retrieved 30 June 2021.
Facher L, Joseph A (28 January 2021). "Novavax says its Covid-19 vaccine is 90% effective in late-stage trial". Stat. Archived from the original on 29 January 2021. Retrieved 29 January 2021.
Johnson L (14 June 2021). "Large study finds that vaccine maker Novavax's shot is about 90% effective". Los Angeles Times. Archived from the original on 18 June 2021. Retrieved 15 June 2021.
Howard J (14 June 2021). "Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial". CNN. Archived from the original on 14 June 2021. Retrieved 14 June 2021.
"EMA receives application for conditional marketing authorisation of Novavax's COVID-19 vaccine, Nuvaxovid". European Medicines Agency (EMA). 17 November 2021. Archived from the original on 1 December 2021. Retrieved 5 December 2021.
"EMA recommends Nuvaxovid for authorisation in the EU" (Press release). European Medicines Agency (EMA). 20 December 2021. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
"Nuvaxovid". Union Register of medicinal products. European Commission. 6 July 2022. Archived from the original on 20 December 2021. Retrieved 23 December 2021.
"Nuvaxovid : EPAR - Product information" (PDF). European Medicines Agency. 5 July 2022. Archived (PDF) from the original on 17 August 2022. Retrieved 11 August 2022.
O'Donnell C, Nadeem D (1 November 2021). "Novavax COVID-19 vaccine receives first emergency use authorization". Reuters. Archived from the original on 24 December 2021. Retrieved 1 November 2021.
"Philippines approves emergency use of Novavax's COVID-19 vaccine". Reuters. 17 November 2021. Archived from the original on 23 December 2021. Retrieved 17 November 2021.
Achom D (28 December 2021). "India Clears 2 New Vaccines And Merck's Covid Pill". NDTV.com. Archived from the original on 28 December 2021. Retrieved 28 December 2021.
Jeong A (12 January 2022). "South Korea approves Novavax coronavirus vaccine". The Washington Post. Archived from the original on 12 January 2022. Retrieved 15 January 2022.
"S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills". Reuters. 12 January 2022. Archived from the original on 15 January 2022. Retrieved 16 January 2022.
"TGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine Nuvaxovid". Therapeutic Goods Administration (TGA) (Press release). 19 January 2022. Archived from the original on 28 January 2022. Retrieved 5 February 2022.
"TGA approves provisional determination for Biocelect Pty Ltd for COVID-19 vaccine, Nuvaxovid". Therapeutic Goods Administration (TGA) (Press release). 10 March 2022. Archived from the original on 8 May 2022. Retrieved 7 May 2022.
Reed J (3 February 2022). "Novavax Covid jab approved by UK drugs regulator". BBC News. Archived from the original on 3 February 2022. Retrieved 3 February 2022.
"Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine" (Press release). Ottawa: Health Canada. 17 February 2022. Archived from the original on 17 February 2022. Retrieved 17 February 2022.
"Novavax's COVID-19 shot authorized in Taiwan for adults". Reuters. 23 June 2022. Archived from the original on 2 July 2022. Retrieved 23 June 2022.
Chong C (14 February 2022). "Novavax Covid-19 vaccine approved for those aged 18 and above in Singapore". The Straits Times. Archived from the original on 9 March 2022. Retrieved 6 March 2022.
Andres G (14 February 2022). "Novavax's Nuvaxovid COVID-19 vaccine granted interim authorisation in Singapore". CNA. Archived from the original on 11 March 2022. Retrieved 6 March 2022.
"WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries" (Press release). World Health Organization (WHO). 17 December 2021. Archived from the original on 24 December 2021. Retrieved 17 December 2021.
Kimball S (9 June 2022). "FDA decision on Novavax's Covid shots could be delayed to review changes in manufacturing". CNBC. Archived from the original on 9 June 2022. Retrieved 9 June 2022.
Khemlani A (7 June 2022). "FDA advisory committee recommends Novavax vaccine for use in adults". Yahoo! Finance. Archived from the original on 9 June 2022. Retrieved 9 June 2022.
Christensen J, Goodman B (13 July 2022). "FDA gives emergency use authorization to Novavax's Covid-19 vaccine". CNN. Archived from the original on 14 July 2022. Retrieved 14 July 2022.
"Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted | FDA". U.S. Food and Drug Administration. 13 July 2022. Archived from the original on 15 July 2022. Retrieved 15 July 2022.
Robbins R, Zimmer C (19 July 2022). "A fourth Covid vaccine is cleared for use in the United States". The New York Times. ISSN 0362-4331. Archived from the original on 21 July 2022. Retrieved 21 July 2022.
"CDC Recommends Novavax's COVID-19 Vaccine for Adults" (Press release). Centers for Disease Control and Prevention. 19 July 2022. Archived from the original on 20 July 2022. Retrieved 21 July 2022.
Neergaard L (19 July 2022). "CDC endorses more traditional Novavax COVID shot for adults". Associated Press. Archived from the original on 22 July 2022. Retrieved 21 July 2022.
"FDA Roundup: August 19, 2022". U.S. Food and Drug Administration (Press release). 19 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022.
"CDC Recommends Novavax COVID-19 Vaccine for Adolescents" (Press release). US Centers for Disease Control and Prevention. 22 August 2022. Archived from the original on 3 September 2022. Retrieved 3 September 2022.
"Novavax COVID-19 Vaccine, Adjuvanted". U.S. Food and Drug Administration (FDA). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
"FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA) (Press release). 30 August 2024. Archived from the original on 4 September 2024. Retrieved 31 August 2024.

who.int (Global: 195^th place; English: 302^nd place)

"WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries" (Press release). World Health Organization (WHO). 17 December 2021. Archived from the original on 24 December 2021. Retrieved 17 December 2021.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". secondary. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". primary. Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. hdl:1959.4/105023. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
Zimmer C (5 April 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. ISSN 0362-4331. Archived from the original on 28 April 2021. Retrieved 23 April 2021.
Robbins R, Zimmer C (19 July 2022). "A fourth Covid vaccine is cleared for use in the United States". The New York Times. ISSN 0362-4331. Archived from the original on 21 July 2022. Retrieved 21 July 2022.

yahoo.com (Global: 38^th place; English: 40^th place)

finance.yahoo.com

Khemlani A (7 June 2022). "FDA advisory committee recommends Novavax vaccine for use in adults". Yahoo! Finance. Archived from the original on 9 June 2022. Retrieved 9 June 2022.

Novavax COVID-19 vaccine (English Wikipedia)

abc.net.au (Global: 139th place; English: 108th place)

aljazeera.com (Global: 268th place; English: 215th place)

apnews.com (Global: 129th place; English: 89th place)

bbc.com (Global: 20th place; English: 30th place)

bizjournals.com (Global: 407th place; English: 241st place)

bloomberg.com (Global: 99th place; English: 77th place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

canada.ca

covid-vaccine.canada.ca

cdc.gov (Global: 218th place; English: 212th place)

channelnewsasia.com (Global: 1,127th place; English: 691st place)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

cnbc.com (Global: 220th place; English: 155th place)

cnn.com (Global: 28th place; English: 26th place)

edition.cnn.com

cnn.com

docs.google.com (Global: 1,047th place; English: 1,015th place)

doi.org (Global: 2nd place; English: 2nd place)

ebc.com.br (Global: 2,752nd place; English: 6,664th place)

agenciabrasil.ebc.com.br

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

ec.europa.eu

fda.gov (Global: 447th place; English: 338th place)

fiercepharma.com (Global: low place; English: 8,921st place)

gazettelive.co.uk (Global: 5,758th place; English: 3,245th place)

globenewswire.com (Global: 2,614th place; English: 1,549th place)

globo.com (Global: 62nd place; English: 304th place)

g1.globo.com

gov.uk (Global: 432nd place; English: 278th place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

hres.ca (Global: low place; English: low place)

pdf.hres.ca

hpr-rps.hres.ca

latimes.com (Global: 22nd place; English: 19th place)

livemint.com (Global: 390th place; English: 227th place)

medpagetoday.com (Global: 9,274th place; English: 5,856th place)

ndtv.com (Global: 138th place; English: 95th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

nih.gov

novavax.com (Global: low place; English: low place)

ir.novavax.com

novavax.com

nps.org.au (Global: low place; English: low place)

nytimes.com (Global: 7th place; English: 7th place)

oclc.org (Global: 1,391st place; English: 1,017th place)

login.uml.idm.oclc.org

reuters.com (Global: 49th place; English: 47th place)

rxfiles.ca (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

statnews.com (Global: 8,771st place; English: 5,253rd place)

straitstimes.com (Global: 543rd place; English: 346th place)

takeda.com (Global: low place; English: low place)

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

tga.gov.au

ebs.tga.gov.au

thackraymuseum.co.uk (Global: low place; English: low place)

collections.thackraymuseum.co.uk

thackraymuseum.co.uk

theguardian.com (Global: 12th place; English: 11th place)

theprint.in (Global: 987th place; English: 560th place)

thisistherealspain.com (Global: low place; English: low place)

washingtonpost.com (Global: 34th place; English: 27th place)

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 195th place; English: 302nd place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

yahoo.com (Global: 38th place; English: 40th place)

finance.yahoo.com

abc.net.au (Global: 139^th place; English: 108^th place)

aljazeera.com (Global: 268^th place; English: 215^th place)

apnews.com (Global: 129^th place; English: 89^th place)

bbc.com (Global: 20^th place; English: 30^th place)

bizjournals.com (Global: 407^th place; English: 241^st place)

bloomberg.com (Global: 99^th place; English: 77^th place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

cdc.gov (Global: 218^th place; English: 212^th place)

channelnewsasia.com (Global: 1,127^th place; English: 691^st place)

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

cnbc.com (Global: 220^th place; English: 155^th place)

cnn.com (Global: 28^th place; English: 26^th place)

docs.google.com (Global: 1,047^th place; English: 1,015^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

ebc.com.br (Global: 2,752^nd place; English: 6,664^th place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

gazettelive.co.uk (Global: 5,758^th place; English: 3,245^th place)

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

globo.com (Global: 62^nd place; English: 304^th place)

gov.uk (Global: 432^nd place; English: 278^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

latimes.com (Global: 22^nd place; English: 19^th place)

livemint.com (Global: 390^th place; English: 227^th place)

medpagetoday.com (Global: 9,274^th place; English: 5,856^th place)

ndtv.com (Global: 138^th place; English: 95^th place)

nih.gov (Global: 4^th place; English: 4^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

oclc.org (Global: 1,391^st place; English: 1,017^th place)

reuters.com (Global: 49^th place; English: 47^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

straitstimes.com (Global: 543^rd place; English: 346^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

theguardian.com (Global: 12^th place; English: 11^th place)

theprint.in (Global: 987^th place; English: 560^th place)

washingtonpost.com (Global: 34^th place; English: 27^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 195^th place; English: 302^nd place)

worldcat.org (Global: 5^th place; English: 5^th place)

yahoo.com (Global: 38^th place; English: 40^th place)